- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 384-398 of
1,261 results
2020 Exhibit: EX2020 Novo Nordisk Production Letter, In re Ozempic Semaglutide ...
Document
IPR2024-00009, No. 2020 Exhibit - EX2020 Novo Nordisk Production Letter, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 17, 2023 REDACTED (P.T.A.B. Jan. 26...
|
|
Cite Document
1012 Exhibit: Lovshin, Incretin Based Therapies for Type 2 Diabetes Mellitus, 5 NA...
Document
IPR2024-00009, No. 1012 Exhibit - Lovshin, Incretin Based Therapies for Type 2 Diabetes Mellitus, 5 NATURE RE (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1008 Exhibit: CV of Paul Dalby, PhD
Document
IPR2024-00009, No. 1008 Exhibit - CV of Paul Dalby, PhD (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1083 Exhibit: Transfer Order, In re Ozempic, No 3038 MDL Aug 5, 2022
Document
IPR2024-00009, No. 1083 Exhibit - Transfer Order, In re Ozempic, No 3038 MDL Aug 5, 2022 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
2007 Exhibit: EX2007 Excerpt of Transcript of Dec 13, 2023 Claim Construction He...
Document
IPR2024-00009, No. 2007 Exhibit - EX2007 Excerpt of Transcript of Dec 13, 2023 Claim Construction Hearing, Novo Nordisk Inc v Mylan Pharmaceuticals Inc, No 23 101 CFC D Del Dec 13, 2023...
|
|
Cite Document
... EX2015 Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,1...
Document
IPR2024-00009, No. 2015 Exhibit - EX2015 Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8...
|
|
Cite Document
2023 Exhibit: EX2023 Notice of Service for Defendants’ Supplemental Invalidity Co...
Document
IPR2024-00009, No. 2023 Exhibit - EX2023 Notice of Service for Defendants’ Supplemental Invalidity Contentions, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Nov...
|
|
Cite Document
1094 Exhibit: CV of Dr John P Fruehauf
Document
IPR2024-00009, No. 1094 Exhibit - CV of Dr John P Fruehauf (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
2011 Exhibit: EX2011 US Patent No 8,114,833
Document
IPR2024-00009, No. 2011 Exhibit - EX2011 US Patent No 8,114,833 (P.T.A.B. Jan. 26, 2024)
|
|
Cite Document
2006 Exhibit: EX2006 Scheduling Order, Novo Nordisk Inc v Rio Biopharms, Inc, No...
Document
IPR2024-00009, No. 2006 Exhibit - EX2006 Scheduling Order, Novo Nordisk Inc v Rio Biopharms, Inc, No 122 cv 00294 CFC, Dkt 22 D Del (P.T.A.B. Jan. 26, 2024)
|
|
Cite Document
2013 Exhibit: EX2013 Waiver of Service of Summons for Dr Reddy’s Laboratories L...
Document
IPR2024-00009, No. 2013 Exhibit - EX2013 Waiver of Service of Summons for Dr Reddy’s Laboratories Ltd, Novo Nordisk Inc v Dr Reddy’s Lab’ys Ltd, No 122 cv 00298 CFC, Dkt 7 D Del Mar 4, 2...
|
|
Cite Document
2002 Exhibit: EX2002 Petition for Inter Partes Review, Mylan Pharms Inc v Novo No...
Document
IPR2024-00009, No. 2002 Exhibit - EX2002 Petition for Inter Partes Review, Mylan Pharms Inc v Novo Nordisk AS, IPR2023 00724, Pap1 Mar 16, 2023 (P.T.A.B. Jan. 26, 2024)
|
|
Cite Document
2021 Exhibit: EX2021 Compilation of Rule 30b1 Deposition Notices, In re Ozempic ...
Document
IPR2024-00009, No. 2021 Exhibit - EX2021 Compilation of Rule 30b1 Deposition Notices, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del (P.T.A.B. Jan. 26, 2024)
|
|
Cite Document
1001 Exhibit: US Patent No 10,335,462
Document
IPR2024-00009, No. 1001 Exhibit - US Patent No 10,335,462 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1068 Exhibit: US Patent No 8,129,343
Document
IPR2024-00009, No. 1068 Exhibit - US Patent No 8,129,343 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
